Login
Navigate Fool.com
Will NVS beat
the market?

Novartis

NYSE: NVS

Community Rating: 5 Stars: The Best

84.67 0.26 (0.31%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $84.35
Previous Close $84.41
Daily Range $84.13 - $84.89
52-Week Range $67.67 - $85.23
Market Cap $205.4B
P/E Ratio 22.88
Dividend (Yield) $2.72 (2.1%)
Ex-Dividend Date
Dividend Pay Date
02/27/14
04/10/14
Volume 969,607
Average Daily Volume 1,504,799
Current FY EPS $5.23

How do you think NVS
will perform against the market?

Top NVS Bull/Bear Pitches

 

MarginofSafetyIn (< 20)
Submitted November 21, 2010

Novartis Review: Could be a good pharma pick Intro Novartis is a “large Pharma” company with 5 major operating units: Branded pharmaceuticals, Generic pharmaceuticals, diagnostics, vaccines and follo … More

0 Replies Reply Report this Post
 

nipous (< 20)
Submitted August 5, 2008

After a good run in the past couple months, NVS looks poised to underperform the S&P. Not that I think its going to take a fall, more so that the S&P will be playing catchup for the next couple of mo … More

0 Replies Reply Report this Post

News & Commentary

Meet the Company That's Changing the Multiple Sclerosis Treatment Landscape

With four multiple sclerosis therapies already approved, another under FDA review, and one more in mid-stage studies, this biopharmaceutical company is addressing this disease head on.

Earnings Primer: What's on Deck for Amgen Inc. and Biogen Idec Inc.

Here's what you need to know about Amgen (AMGN) and Biogen's (BIIB) upcoming first quarter earnings report.

Foreign Stocks: Balance Your Portfolio and Profit From Global Growth

Foreign stocks like Banco Santander, Novartis AG, and Vodafone Group also offer hefty dividends -- one yields 6.6%.

Does Pfizer Offer Good Value?

With a recent P/E ratio in single digits, Pfizer may be the last value play in the pharmaceutical industry.

Cyclacel Pharmaceuticals, Inc. (CYCCP) Ex-Dividend Date Scheduled for April 15, 2014

Can This Drug Be a Game Changer for Eli Lilly?

Eli Lilly's experimental breast cancer drug is reporting strong results in an early-stage trial. Here is what you need to know going forward.

3 Breast Cancer Drugs With Big Potential

CDK 4/6 Inhibitor breast cancer drugs from Pfizer (PFE), Novartis (NVS), and Lilly (LLY) are making their way through trials and may soon give patients and doctors a new, important weapon in HER2 positive breast cancer.

The Biggest Biotech Clinical Wins of the Week

See which big biotech and pharmaceutical companies got the best clinical results for the week ending April 4.

5 Stocks Forging the Future of Breast Cancer Care

Pharmacotherapies for breast cancer are undergoing an innovation boom. Which biotechs offer the most compelling investment opportunities in this space?

Pfizer Inc's Palbociclib Delivers the Goods

Palbociclib looks poised to be a multibillion-dollar drug for Pfizer.

See More NVS News...

Sector

Healthcare

Industry

Drugs

Novartis (NVS) Description

Operates in the business of patent-protected and generic pharmaceuticals as well as consumer health products. Website: http://www.novartis.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks